UNASSIGNED: Purpose Our aim was to determine the role of end-of-induction (EOI) @entity41 ( @entity41 ) assessment in the identification and stratification of induction failure in @entity1 with pediatric @entity981 ( @entity981 ) and to identify @entity74 that @entity66 in these @entity1 . @entity1 and Methods Analysis included 3,113 @entity1 who were treated in the Medical Research Council UKALL2003 multicenter randomized trial (NCT00222612) between 2003 and 2011. @entity41 was measured by using standardized real-time quantitative PCR. Median follow-up was 5 years 9 months. Results Fifty-nine @entity1 (1.9%) had morphologic induction failure with 5-year event-free survival (EFS) of 50.7% (95% CI, 37.4 to 64.0) and 5-year overall survival of 57.7% (95% CI, 44.2 to 71.2). Of these, a small proportion of @entity1 with M2 marrow (6 of 44) and a low EOI @entity41 level (< 0.01%) had 5-year EFS of 100%. Conversely, among @entity1 with morphologic remission 2.3% (61 of 2,633) had high @entity41 (>=  5%) and 5-year EFS of 47.0% (95% CI, 32.9 to 61.1), which was similar to those with morphologic induction failure. Redefining induction failure to include morphologic induction failure and/or @entity41 >=  5% identified 3.9% (120 of 3,133 @entity1 ) of the trial cohort with 5-year EFS of 48.0% (95% CI, 39.3 to 58.6). Induction failure (morphologic or @entity41 >=  5%) occurred most frequently in @entity981 (10.1%; 39 of 386 @entity981 cases) and B-other @entity981 , that is, lacking established @entity2008 (5.6%; 43 of 772 B-other cases). Genetic testing within the B-other group revealed the presence of @entity3820 gene fusions, particularly @entity31493 - @entity3820 , in almost one third of B-other @entity981 cases. Conclusion Integration of EOI @entity41 level with morphology identifies induction failure more precisely than morphology alone. Prevalence of @entity31493 - @entity3820 fusions in this group highlights the importance of genetic screening to identify abnormalities that may be targets for novel agents.

Use of Minimal Residual Disease Assessment to Redefine Induction Failure in XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity981 :: ('MESH:D054198', 'Disease') :: ['T-ALL', 'ALL', 'acute lymphoblastic leukemia'] @entity66 :: ('MESH:D004194', 'Disease') :: ['drive disease'] @entity41 :: ('MESH:D018365', 'Disease') :: ['MRD', 'minimal residual disease'] @entity31493 :: ('1879', 'Gene') :: ['EBF1'] @entity3820 :: ('5159', 'Gene') :: ['PDGFRB'] @entity74 :: ('MESH:D030342', 'Disease') :: ['genetic abnormalities'] @entity2008 :: ('MESH:D002869', 'Disease') :: ['chromosomal abnormalities']
@entity981 :: (MESH:D054198,Disease) :: ['Pediatric Acute Lymphoblastic Leukemia']
